Oncology Consults: Addressing Unmet Needs in Mesothelioma
PROGRAM DESCRIPTION Malignant pleural mesothelioma (MPM) is a relatively rare but serious malignancy that arises from the mesothelial surfaces of the pleural cavity. Recently, a growing body of research has ...
Malignant pleural mesothelioma (MPM) is a relatively rare but serious malignancy that arises from the mesothelial surfaces of the pleural cavity. Recently, a growing body of research has demonstrated that angiogenesis is an important part of the pathophysiology for many types of cancer, including MPM, and angiogenesis inhibitors have increasingly been used to treat patients with MPM. Although not yet approved by the US Food and Drug Administration (FDA), evidence-based guidelines recommend the addition of the anti-angiogenesis agent bevacizumab, to pemetrexed and cisplatin for select MPM patients. Several oral angiogenesis inhibitors (also referred to as angiokinase inhibitors) are being developed for treating patients with MPM. This activity will explore the challenges in the current care of patients with MPM and prospects for improved, more personalized therapy approaches in the future.
After participating in this activity, the participant will demonstrate the ability to:RECOGNIZE clinical challenges and unmet needs associated with MPM diagnosis and treatment.DESCRIBE the role of and rationale for targeting angiogenesis in MPM.EVALUATE available data and potential clinical implications of investigational angiokinase inhibitors for MPM.The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.
I'm interested in this
Share with others
Write the first review
Share with others